Skip to main content
Premium Trial:

Request an Annual Quote

XDx's AlloMap Gets Positive Determination from Aetna

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Aetna has determined that the firm's AlloMap test is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.

"Recognition of AlloMap's benefit for eligible heart transplant recipients by one of the leading providers of health care in the United States is an important validation of our tests and results," Pierre Cassigneul, president and CEO of Brisbane, Calif.-based XDx, said in a statement. "We hope to reduce the number of invasive biopsies that stable patients have to undergo post-transplant and thereby improve patients' quality of life."

XDx received US Food and Drug Administration clearance for AlloMap in 2008. The test is a non-invasive, multi-gene expression assay used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with a standard clinical assessment.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.